San Nuo Bio: The appeal against the overseas related patent infringement was rejected, maintaining the previous preliminary injunction ruling.

On April 1, Sannuo Biologics released an announcement stating that the Appeals Court of the Unified Patent Court for Europe (UPC) dismissed the company’s and A Menarini Diagnostics S.r.l.’s appeal requests and upheld the interim injunction ruling issued by the Hague UPC Division for the GlucoMen iCan CGM product.

The announcement mentioned that the Unified Patent Court for Europe ruling covered by this announcement is the outcome of the appeal regarding a “Preliminary Injunction (PI),” and is not a final ruling on the merits of the case. The interim injunction was a precautionary measure taken before the final hearing of the case and does not represent the court’s final determination on whether infringement occurred or whether the patent is valid. The estimated amount involved in this ruling is €200,000–€400k.

The company is actively preparing for the plaintiff’s and defendant’s proceedings and responses regarding the case. Since the plaintiff’s case has not yet opened for trial, the outcome of the final judgment remains uncertain, and the specific impact on the company’s post-event profits is also uncertain.

(Sannuo Biologics announcement)

(Edited by: Yang Yan, Lin Chen)

Key words:

                                                            Medical